MEMPHIS, Tenn.--(BUSINESS WIRE)--Solana Surgical, LLC (Solana), a growth extremity company, announces the FDA Clearance of the CrossCHECK™ Plating System, a new implant system for orthopedic and podiatric surgeons’ use in foot and ankle procedures. Commercialization will follow in the first quarter of 2014.
The first phase of commercialization will include plates that will be primarily used for stabilization and fixation (leading to fusion) in the forefoot and mid-foot. Fusion is often the preferred procedure to relieve pain and correct skeletal alignment issues in patients with arthritis, as well as small joint fractures and bunions.
Unlike other plating systems on the market, the CrossCHECK™ System offers unique compression and stabilization features: the plates are manufactured with a Type II anodization, which enhances the fatigue strength of the device, and thus improves stabilization. In addition, specially designed ridges are built into the plates to enhance grip, and act as a buttress during the compression process. “Studies have shown that similar ridges can also improve host bone health,” explains Rebecca Wahl, Vice President of Research and Development.
The CrossCHECK Plating System offers various sizes and configurations for specific surgical needs.
The CrossCHECK System joins a growing family of Solana Surgical products that include the FuseFORCE™ Fixation System, TenFUSE™ PIP with Sterile Instruments, TenFUSE™ Nail, SolaFIX™ Screw System, MDI Metatarsal Decompression Implant, LMH Lesser Metatarsal Head Implant, TenSIX™ Acellular Dermal Tissue, TenSIX™ Cancellous Sponge, TenSIX™ Moldable Putty and the GaitWAY™ Implant System.
About Solana Surgical
Solana Surgical, LLC is a global extremity orthopedic company that develops breakthrough solutions to restore motion while relieving pain for patients, and that improve surgical outcomes for surgeons. Having launched its first product in 2011, Solana Surgical’s goal is to advance the science in the foot, ankle and hand markets by meeting unmet needs with innovative new products. For more information, please visit www.SolanaSurgical.com.
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements made in this press release, other than statements of historical fact, are forward-looking statements. Forward-looking statements reflect management’s current views of future performance, results, and trends and may be identified by their use of terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “will,” and other similar terms. The Company wishes to caution readers that actual results might differ materially from those described in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties impacting Solana Surgical LLC’s business, including increased competition, technical obsolescence, regulatory issues, general economic conditions and other risks.